Perseus Proteomics, Inc. (JP:4882) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Perseus Proteomics, Inc. has announced the publication of an abstract for its radiopharmaceutical therapy, PPMX-T002, aimed at treating solid cancers, at the EANM ’24 Annual Congress. PPMX-T002 targets the cadherin 3 protein on various solid tumors and has shown enhanced efficacy in preclinical trials when using Actinium 225 compared to Yttrium 90.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.